Furthermore, our study utilized an intention-to-treat approach [46, 47], comparing the effects of being assigned to the treatment strategies at baseline, regardless of whether participants followed these strategies throughout the follow-up period
Finally, while many people experience positive results, not every patient qualifies, and some will find alternative approaches to be a better fit
SOURCE: NYU Langone Health, news release, March 5, 2025 What This Means For You Kidney transplant patients may wish to ask their doctor if a GLP-1 drug could help them.
What's the difference between GLP-1 receptor agonists and DPP-4 inhibitors for appetite control
FDA approval is expected in 2027 or 2028